Z 100

Drug Profile

Z 100

Alternative Names: Ancer-20; SSM; Z-100

Latest Information Update: 20 Nov 2015

Price : $50

At a glance

  • Originator Zeria
  • Class Anti-inflammatories; Antineoplastics; Antivirals; Lipids; Mannans
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Leucopenia
  • Phase III Cervical cancer
  • Discontinued HIV infections; Rheumatoid arthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 08 May 2015 Z 100 is still in phase III trials for Cervical cancer in Japan
  • 01 Dec 2014 Phase-III clinical trials in Cervical cancer (First-line therapy, Late-stage disease) in Thailand, Malaysia, Singapore, South Korea, Taiwan and Vietnam, Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top